Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck. - Barron's
1. Citi analysts downgrade AbbVie to Neutral, citing pipeline concerns. 2. Pharma tariffs and pricing policies create uncertainty in the sector. 3. AbbVie retains strong fundamentals but faces pipeline scrutiny. 4. Historical context shows the industry's volatility with regulatory changes. 5. Regeneron emerges as a preferred investment over AbbVie and Merck.